Here are relevant reports on : infectious-disease-diagnostics-market
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Test Strips Market by Product Type (Blood test strip, Urine Test Strip), Application (Diabetes, Infectious Disease, Cardiac Marker Testing), End-use (Hospitals, Home Care, Diagnostic Laboratories) - Global Forecast to 2027
The global test strips market is projected to reach USD 12.9 billion by 2027 from USD 11.4 billion in 2021, at a CAGR of 2.1% during the forecast period . The growth of test strips market is owing to Increasing prevalence of diabetes across the globe, rising preference for point of care testing, and increasing technological advancements in test strips whereas the low accuracy of test strips are restraining this market up to certain extent.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Europe Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Europe biomarkers Market, valued at US$16.40 billion in 2024, stood at US$17.46 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$28.11 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030
The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030
The global biomarkers market, valued at USD 58.07 billion in 2024, stood at USD 62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of USD 104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: May 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
